|
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
|
5R01CA116019-04
|
$292,084
|
$73,021
|
AKHURST, ROSEMARY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
|
5R21CA139814-02
|
$236,417
|
$236,417
|
BENARD, FRANCOIS
|
BRITISH COLUMBIA CANCER AGENCY
|
|
2010 Mammary Gland Biology GRC
|
1R13CA150225-01
|
$10,000
|
$5,000
|
JERRY, D
|
GORDON RESEARCH CONFERENCES
|
|
3D-adhesion stromagenesis in cancer permissiveness
|
5R01CA113451-05
|
$240,604
|
$240,604
|
CUKIERMAN, EDNA
|
INSTITUTE FOR CANCER RESEARCH
|
|
3D-Nanostrcutured Substrates for Detection of Circulating Tumor Cells
|
1R21CA151159-01
|
$167,475
|
$167,475
|
TSENG, HSIAN-RONG
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A 3D microfluidic platform for quantitative assessments of tumor cell migration
|
1R21CA138366-01A2
|
$190,590
|
$190,590
|
Wu, Mingming
|
CORNELL UNIVERSITY ITHACA
|
|
A Cellular and Molecular Analysis of the Intravasation Step in Tumor Metastasis
|
5R01CA129484-03
|
$393,213
|
$393,213
|
QUIGLEY, JAMES
|
SCRIPPS RESEARCH INSTITUTE
|
|
A Genetic Screen for HCC Genes
|
1R01CA132962-01A2
|
$325,038
|
$325,038
|
LARGAESPADA, DAVID
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-04
|
$189,600
|
$189,600
|
HOLMEN, SHERI
|
NEVADA CANCER INSTITUTE
|
|
A Human Intraepithelial Tumor Microenvironment Assay
|
2R42CA118684-02A2
|
$614,540
|
$614,540
|
Allen-Hoffmann, Barbara
|
STRATATECH CORPORATION
|
|
A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
|
3R01CA072038-13S1
|
$51,581
|
$17,022
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
|
5R01CA072038-13
|
$300,198
|
$99,065
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Mitogen-induced G Protein-coupled Receptor
|
ZIA SC 009389
|
$49,274
|
$49,274
|
Kelly, Kathleen
|
CCR (NCI)
|
|
A Mouse model of TGFbeta1 and ras oncogene interactions
|
5R01CA122109-05
|
$238,266
|
$59,567
|
GLICK, ADAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
A new radiopharmaceutical for the treatment of metastatic bone cancer
|
1R43CA150601-01A1
|
$143,582
|
$143,582
|
Simon, Jaime
|
ISOTHERAPEUTICS GROUP, LLC
|
|
A Novel Dose Calculation Method for Targeted Radionuclide Therapy
|
1R01CA138986-01A2
|
$326,165
|
$163,083
|
MOURTADA, FIRAS
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A Novel Expansion of Primary Leukemia Stem Cells
|
1R43CA156921-01
|
$304,943
|
$304,943
|
SAKTHIVEL, RAMASAMY
|
ARTERIOCYTE, INC.
|
|
A novel function of TIMP-1
|
5R01CA089113-08
|
$269,442
|
$67,361
|
KIM, HYEONG-REH
|
WAYNE STATE UNIVERSITY
|
|
A novel growth regulatory factor in breast cells
|
5R01CA092440-08
|
$314,000
|
$78,500
|
MONTANO, MONICA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Novel Oncolytic HSP Vaccine for Systemic Tumor Therapy
|
5R01CA100841-05
|
$224,174
|
$112,087
|
HUANG, XUE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$331,251
|
$231,876
|
Merlino, Glenn
|
CCR (NCI)
|
|
A Novel Regulator of Cancer Cell Migration and Invasion
|
5R01CA115706-05
|
$195,792
|
$195,792
|
ALAHARI, SURESH
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer
|
1R43CA139644-01A1
|
$202,678
|
$202,678
|
Hill, Samuel
|
ROGERS SCIENCES, INC.
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-23
|
$236,943
|
$59,236
|
Lozano, Guillermina
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
|
5R21CA139473-02
|
$343,200
|
$343,200
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A primary human xenograft model of pancreatic cancer.
|
5R03CA141245-02
|
$75,750
|
$75,750
|
BAUER, TODD
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
|
A program of immune-based treatments for cancer
|
7K24CA093670-08
|
$182,273
|
$45,568
|
CARSON, WILLIAM
|
OHIO STATE UNIVERSITY
|
|
A Proteomics-based Approach to Identifying Mechanisms of Drug Resistance to Targe
|
1F32CA154052-01
|
$47,606
|
$47,606
|
Stuart, Scott
|
UNIVERSITY OF COLORADO AT BOULDER
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
5R01CA131197-03
|
$578,839
|
$578,839
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
A Role of Novel Serpin Maspinin Prostate Tumor/Bone Interaction
|
5R01CA127735-03
|
$312,288
|
$312,288
|
SHENG, SHIJIE
|
WAYNE STATE UNIVERSITY
|
|
A Structure/function Analysis of a Tumor Specific Protein
|
5R01CA121289-04
|
$287,850
|
$287,850
|
MALKAS, LINDA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
|
5U01CA084244-12
|
$826,688
|
$82,669
|
BALMAIN, ALLAN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Abi pathway in Breast Cancer Metastasis
|
5R21CA133597-02
|
$196,020
|
$196,020
|
DAI, ZONGHAN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Abl Kinases in growth factor signaling, motility, and invasion
|
5R01CA116784-04
|
$267,536
|
$267,536
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S6
|
$7,064,076
|
$494,485
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S7
|
$100,000
|
$7,000
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S8
|
$50,000
|
$3,500
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Ack1: A Critical Regulator of Hormone-Refractory Prostate Cancer
|
1R01CA135328-01A1
|
$352,581
|
$352,581
|
Mahajan, Nupam
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
ACOSOG Central Specimen Bank
|
3U24CA114736-05S1
|
$577,571
|
$57,757
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
Activated nano-sized MR contrast agents for imaging of tumor proteolytic activity
|
5R21CA133288-02
|
$216,480
|
$216,480
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
3P01CA128913-03S1
|
$79,000
|
$14,220
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Activation of Plasmacytoid Dendritic Cells (pDCs) to Induce Antitumor Activity
|
5P01CA128913-03
|
$1,837,241
|
$330,703
|
HWU, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
ACTIVIN SIGNALING AND REGULATION IN THE COLON
|
1R01CA141057-01A2
|
$279,565
|
$139,783
|
JUNG, BARBARA
|
NORTHWESTERN UNIVERSITY
|
|
Adenosine in Tumor-Host Interaction
|
1R01CA138923-01A2
|
$160,813
|
$40,203
|
DIKOV, MIKHAIL
|
VANDERBILT UNIVERSITY
|
|
Adhesive regulation during cell migration
|
2R01CA085862-11A1
|
$286,863
|
$286,863
|
HUTTENLOCHER, ANNA
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Adiposity and Outcomes of Clinically Localized Prostate Cancer
|
5R01CA129140-02
|
$628,470
|
$628,470
|
Freeman, Vincent
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
ADJUVANT TRIAL WITH SOY AFTER RADICAL PROSTATECTOMY
|
5R01CA116195-06
|
$251,751
|
$251,751
|
BOSLAND, MAARTEN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
5R01CA134844-02
|
$321,841
|
$321,841
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
Adoptive T Cell Therapy Following CD25 Lymphodepletion
|
5R21CA137647-02
|
$350,828
|
$350,828
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1
|
2R01CA104711-06A2
|
$392,915
|
$392,915
|
YEE, CASSIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Metastasis for this search: $385,223,790
|